Replies to post #280233 on Innovation Pharmaceuticals Inc (IPIX)

[Empiricst1]

No, IPIX was as long as it retained the license to do gram-negative bacterial. IPIX stopped paying for that last license last year as I recall. Quite a long a circuitous chain including KarinCA, lr and others was presented here on this mb. You must have missed the chain. Of course IPIX still has the great data from the B for ABSSSI 2b, but that is mainly for gram-positive bacteria, which tend to be skin-rellated, as opposed to the colorectal siting of the more dangerous gram-negative.

[Lemoncat]

“We urgently need research and development,” said Sarah Paulin, technical officer of Antimicrobial Resistance and Innovation at the W.H.O. and an author of two reports on the subject issued Friday. “We still have a window of opportunity but we need to ensure there is investment now so we don’t run out of options for future generations.”

We did it. We stepped up and did the research and paid the expenses to do so. Our trial and drug candidate succeeded with flying colors. What was our reward? Five years later, still no partnership and a 97% loss.

Who is going to pay for this research when the economics do not incentivize it? Whatever market forces have held back B-ABSSSI will continue to hold it and other new treatments back in the future.

BK - These sorts of articles have been in the news for decades. It ended up being an unsound investment thesis five years ago. Why do you feel it is different now?

Go IPIX!